MedTrace Logo

Study in Parkinson's Disease of Exercise

NCT01506479 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2017-10-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn more about the effects of exercise on patients who have been recently diagnosed with Parkinson's disease (PD). The investigators are going to test two levels of exercise (moderate to vigorous) against no exercise. The investigators think that exercise may reduce the symptoms the of PD, and the investigators hope to learn what level of exercise will offer the most benefit.

Conditions

  • Parkinson Disease

Interventions

BEHAVIORAL

Moderate Exercise

Endurance exercise at 60 - 65% heart rate (HR) max,4x/wk for 6 months.

BEHAVIORAL

Vigorous Exercise

Endurance exercise at 80-85% HR max, 4x/wk for 6 months.

BEHAVIORAL

No Intervention

No-exercise control (i.e., usual care);

Sponsors & Collaborators

  • University of Illinois at Chicago

    collaborator OTHER

  • University of Pittsburgh

    collaborator OTHER

  • Rush University Medical Center

    collaborator OTHER

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Northwestern University

    collaborator OTHER

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Margaret Schenkman, PT, PhD · University of Colorado, Denver

  • Daniel Corcos, PhD · University of Illinois at Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01506479 on ClinicalTrials.gov